FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who Have Symptomatic Plexiform Neurofibromas Not Amenable to Complete Resection By Ogkologos - March 20, 2025 785 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ReNeu study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Lung cancer screening can’t leave anyone in the UK behind July 27, 2023 Workout Wednesdays – Leg Exercises Part 3 June 24, 2020 EMA Recommends Granting a Marketing Authorisation for Fruquintinib May 13, 2024 Adagrasib Shows Promising Activity as Monotherapy, Even Greater in Combination with... January 11, 2023 Load more HOT NEWS Understanding the Risk of Second Cancers After CAR T-Cell Therapy EMA Recommends Extension of Therapeutic Indications for Olaparib Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Trial Produces Practice-Changing Findings for Some Children, Young Adults with Leukemia
